Novavax Inc said on Tuesday its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.
The authorization is a global first for the age group for the vaccine, which is manufactured and marketed in India by the Serum Institute of India under the brand name Covovax.
Novavax last month said its vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.
The company said on Tuesday its vaccine produced an immune response in the same age group in a mid- to late-stage study involving 460 Indian adolescents.
Covovax is the fourth COVID-19 vaccine to be authorised for adolescents aged 12 years and older in India after Biological E's Corbevax, Zydus Cadila's ZyCoV-D and Bharat Biotech's Covaxin.
India, which had so far been vaccinating children aged 15 and above, started administering doses of Biological E's Corbevax last week to children aged 12 to 14.
The country's drug regulator in December authorised Novavax's COVID-19 vaccine for people aged 18 years and above.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Covid mRNA Vaccines Contributing To Deaths, Doctors Call For Suspension Covid Virus Remains In Skull For Years After Infection: Study Long Covid Appears To Be Driven By 'Long Infection'. Here's What Science Says Is Safe Car Enough? Volvo Crash That Killed CEO, Family Sparks Big Question "Nothing Short Of Nightmare": Woman Misses Life Event, Slams Air India Snack Food Epigamia Founder Rohan Mirchandani Dies Of Cardiac Arrest At 41 Watch: Pak Girl Selling Snacks Speaks Flawless English, Impresses Internet Key Challenges Gen Z Students Face Abroad And How to Overcome Them Rahul Gandhi's Family Lunch At Iconic Delhi Restaurant Track Latest News Live on NDTV.com and get news updates from India and around the world.